Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 502

1.

[Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer].

Němeček R, Svoboda M, Slabý O.

Klin Onkol. 2016;29(3):187-95. Czech.

PMID:
27296403
2.

Case 3: Episodic Weakness in an 18-month-old Girl.

Dietz M, Jones M, Svoboda M, Finanger E.

Pediatr Rev. 2016 May;37(5):218-9. doi: 10.1542/pir.2016-0021. No abstract available.

PMID:
27139332
3.

[Editorial].

Fait V, Svoboda M.

Klin Onkol. 2016;29(1):5. Czech. No abstract available.

PMID:
27011955
4.

Exploring the role of sphingolipid machinery during the epithelial to mesenchymal transition program using an integrative approach.

Meshcheryakova A, Svoboda M, Tahir A, Köfeler HC, Triebl A, Mungenast F, Heinze G, Gerner C, Zimmermann P, Jaritz M, Mechtcheriakova D.

Oncotarget. 2016 Mar 7. doi: 10.18632/oncotarget.7947. [Epub ahead of print]

5.

Long-term approach to patients with postsurgical seizures.

Ryzí M, Ošlejšková H, Rektor I, Novák Z, Hemza J, Chrastina J, Svoboda M, Hermanová M, Brázdil M.

Epilepsia. 2016 Apr;57(4):597-604. doi: 10.1111/epi.13343. Epub 2016 Feb 26.

PMID:
26921146
6.

Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients.

Iliev R, Stanik M, Fedorko M, Poprach A, Vychytilova-Faltejskova P, Slaba K, Svoboda M, Fabian P, Pacik D, Dolezel J, Slaby O.

Onco Targets Ther. 2016 Jan 8;9:217-22. doi: 10.2147/OTT.S91295. eCollection 2016.

7.

Atomization of Bismuthane in a Dielectric Barrier Discharge: A Mechanistic Study.

Kratzer J, Zelina O, Svoboda M, Sturgeon RE, Mester Z, Dědina J.

Anal Chem. 2016 Feb 2;88(3):1804-11. doi: 10.1021/acs.analchem.5b04095. Epub 2016 Jan 21.

PMID:
26796626
8.

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group.

Eur Urol. 2015 Dec 30. pii: S0302-2838(15)01240-3. doi: 10.1016/j.eururo.2015.12.031. [Epub ahead of print]

PMID:
26746623
9.

MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.

Hezova R, Kovarikova A, Srovnal J, Zemanova M, Harustiak T, Ehrmann J, Hajduch M, Sachlova M, Svoboda M, Slaby O.

Tumour Biol. 2016 Jun;37(6):8007-18. doi: 10.1007/s13277-015-4656-8. Epub 2015 Dec 28.

PMID:
26711784
10.

[Editorial].

Svoboda M.

Klin Onkol. 2015;28 Suppl 4:4S3. Czech. No abstract available.

PMID:
26702459
11.

MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response.

Besse A, Sana J, Lakomy R, Kren L, Fadrus P, Smrcka M, Hermanova M, Jancalek R, Reguli S, Lipina R, Svoboda M, Slampa P, Slaby O.

Tumour Biol. 2016 Jun;37(6):7719-27. doi: 10.1007/s13277-015-4654-x. Epub 2015 Dec 21.

PMID:
26692101
12.

[Retrospective NGS Study in High-risk Hereditary Cancer Patients at Masaryk Memorial Cancer Institute].

Macháčková E, Hazova J, Sťahlová Hrabincová E, Vašíčková P, Navrátilová M, Svoboda M, Foretová L.

Klin Onkol. 2016;29 Suppl 1:S35-45. Czech.

PMID:
26691941
13.

[Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome].

Foretová L, Macháčková E, Palácová M, Navrátilová M, Svoboda M, Petráková K.

Klin Onkol. 2016;29 Suppl 1:S9-13. Czech.

PMID:
26691937
14.

[Immunotherapy for the Prevention and Treatment of Breast Cancer].

Svoboda M, Navrátil J, Slabý O.

Klin Onkol. 2015;28(6):416-25. Review. Czech.

PMID:
26673991
15.

[Triple Negative Breast Cancer].

Navrátil J, Fabian P, Palácová M, Petráková K, Vyzula R, Svoboda M.

Klin Onkol. 2015;28(6):405-15. Review. Czech.

PMID:
26673990
16.

Could tight junctions regulate the barrier function of the aged skin?

Svoboda M, Bílková Z, Muthný T.

J Dermatol Sci. 2016 Mar;81(3):147-52. doi: 10.1016/j.jdermsci.2015.11.009. Epub 2015 Nov 28. Review.

PMID:
26639794
17.

Old World megadroughts and pluvials during the Common Era.

Cook ER, Seager R, Kushnir Y, Briffa KR, Büntgen U, Frank D, Krusic PJ, Tegel W, van der Schrier G, Andreu-Hayles L, Baillie M, Baittinger C, Bleicher N, Bonde N, Brown D, Carrer M, Cooper R, Čufar K, Dittmar C, Esper J, Griggs C, Gunnarson B, Günther B, Gutierrez E, Haneca K, Helama S, Herzig F, Heussner KU, Hofmann J, Janda P, Kontic R, Köse N, Kyncl T, Levanič T, Linderholm H, Manning S, Melvin TM, Miles D, Neuwirth B, Nicolussi K, Nola P, Panayotov M, Popa I, Rothe A, Seftigen K, Seim A, Svarva H, Svoboda M, Thun T, Timonen M, Touchan R, Trotsiuk V, Trouet V, Walder F, Ważny T, Wilson R, Zang C.

Sci Adv. 2015 Nov 6;1(10):e1500561. doi: 10.1126/sciadv.1500561. eCollection 2015 Nov.

18.

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek R, Slaby O, Negrini M.

BMC Cancer. 2015 Oct 27;15:808. doi: 10.1186/s12885-015-1752-5.

19.

Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer.

Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, Slaby O.

Oncotarget. 2016 Jan 5;7(1):622-37. doi: 10.18632/oncotarget.5807.

20.

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.

Mlcochova J, Faltejskova-Vychytilova P, Ferracin M, Zagatti B, Radova L, Svoboda M, Nemecek R, John S, Kiss I, Vyzula R, Negrini M, Slaby O.

Oncotarget. 2015 Nov 17;6(36):38695-704. doi: 10.18632/oncotarget.5735.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk